Go Pro
NASDAQ:HYPD

Hyperion DeFi Q4 2025 Earnings Report

Hyperion DeFi logo
$2.51 -0.13 (-4.92%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$2.51 0.00 (0.00%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hyperion DeFi EPS Results

Actual EPS
-$7.76
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hyperion DeFi Revenue Results

Actual Revenue
$0.50 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hyperion DeFi Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Hyperion DeFi Earnings Headlines

Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answer to a multi-variable problem. Withdrawal sequencing, sequence-of-returns risk, Roth conversion timing, and legacy goals can all shift your real number significantly. Research from Vanguard suggests advisor best practices - covering allocation, rebalancing, tax management, and behavioral coaching - may add roughly 3% in net annual return potential. Morningstar's 2025 data shows the average investor return gap is 1.2% per year due to mistimed buying and selling. Get matched with a fiduciary advisor in your area at no cost and with no obligation to hire.tc pixel
Hyperion Gains on Blockdaemon Hookup
See More Hyperion DeFi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hyperion DeFi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hyperion DeFi and other key companies, straight to your email.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Hyperion DeFi Profile